NOVAVAX INC Available-for-sale Securities, Amortized Cost Basis
NOVAVAX INC (NVAX) had Available-for-sale Securities, Amortized Cost Basis of $0 as of 2019-06-30, per its 10-Q filed 2019-08-07.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAmortizedCost · last filed 2019-08-07
- 2019-06-30: Available-for-sale Securities, Amortized Cost Basis $0.00.
- 2019-03-31: Available-for-sale Securities, Amortized Cost Basis $2.48M.
- 2018-12-31: Available-for-sale Securities, Amortized Cost Basis $21.98M.
- 2018-09-30: Available-for-sale Securities, Amortized Cost Basis $70.62M.
| Period end | Available-for-sale Securities, Amortized Cost Basis |
|---|---|
| 2019-06-30 | $0.00 10-Q · filed 2019-08-07 |
| 2019-03-31 | $2.48M 10-Q · filed 2019-05-02 |
| 2018-12-31 | $21.98M 10-Q · filed 2019-08-07 |
| 2018-09-30 | $70.62M 10-Q · filed 2018-11-07 |
| 2018-06-30 | $78.63M 10-Q · filed 2018-08-08 |
| 2018-03-31 | $30.37M 10-Q · filed 2018-05-09 |
| 2017-12-31 | $51.01M 10-K · filed 2019-03-18 |
| 2017-09-30 | $68.32M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $111.52M 10-Q · filed 2017-08-08 |
| 2017-03-31 | $115.30M 10-Q · filed 2017-05-08 |
| 2016-12-31 | $91.09M 10-K · filed 2018-03-14 |
| 2016-09-30 | $180.18M 10-Q · filed 2016-11-09 |
| 2016-06-30 | $276.69M 10-Q · filed 2016-08-09 |
| 2016-03-31 | $301.35M 10-Q · filed 2016-05-05 |
| 2015-12-31 | $137.57M 10-K · filed 2017-02-27 |
| 2015-09-30 | $152.01M 10-Q · filed 2015-11-09 |
| 2015-06-30 | $147.57M 10-Q · filed 2015-08-10 |
| 2015-03-31 | $112.70M 10-Q · filed 2015-05-07 |
| 2014-12-31 | $135.79M 10-K · filed 2016-02-29 |
| 2014-09-30 | $155.83M 10-Q · filed 2014-11-06 |
| 2014-06-30 | $104.92M 10-Q · filed 2014-08-07 |
| 2014-03-31 | $2.91M 10-Q · filed 2014-05-08 |
| 2013-12-31 | $12.98M 10-K · filed 2015-02-27 |
| 2013-09-30 | $23.31M 10-Q · filed 2013-11-12 |
| 2013-06-30 | $37.39M 10-Q · filed 2013-08-08 |
| 2013-03-31 | $35.90M 10-Q · filed 2013-05-09 |
| 2012-12-31 | $32.52M 10-K · filed 2014-03-12 |
| 2012-09-30 | $16.64M 10-Q · filed 2012-11-09 |
| 2012-06-30 | $10.26M 10-Q · filed 2012-08-09 |
| 2011-12-31 | $3.37M 10-K · filed 2013-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |